Filter your results
- 1
- 1
- 2
- 2
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN).Journal of Clinical Oncology, 2016, 34 (2)
Journal articles
hal-01361499v1
|
|||
|
Classification of Patients With GH Disorders May Vary According to the IGF-I AssayJournal of Clinical Endocrinology and Metabolism, 2017, 102 (8), pp.2844-2852. ⟨10.1210/jc.2017-00202⟩
Journal articles
hal-01579404v1
|